On December 14, 1799, physicians drained about 40 percent of George Washington’s blood over 12 hours to treat a swollen throat. He died that night.
The physicians were competent and confident. Medicine in 1799 held that fever meant too much blood, and too much blood meant the lancet. Washington agreed, ordering the first cut himself and demanding more as the day wore on, over his wife’s pleas. The treatment fit the theory perfectly. The theory fit the wrong disease. Modern physicians generally believe an infection of the epiglottis was swelling his airway shut, and no amount of draining could reach it.
The Bangko Sentral ng Pilipinas (BSP) made the same kind of call on October 22, raising its benchmark rate 50 basis points to 5.5 percent, the fourth hike in a row and 125 basis points of tightening since April. September inflation was 7.2 percent, October then came in at 7.8 percent and Governor Eli Remolona Jr. said the board feared falling behind the curve. The Monetary Board meets again on December 17, and the only question that matters is the diagnosis.
Inflation comes in two kinds, demand-pull and cost-push, and they need opposite treatment. Demand-pull is too much money chasing too few goods. Households and firms want more than the economy can deliver, and they bid prices up against each other. Higher interest rates cure it. Borrowing gets more costly, spending cools and demand falls back into line with supply.
Cost-push is the other kind. Oil, freight, imported inputs and a weak peso make production and delivery cost more, and producers raise prices to stay in business regardless of whether buyers are plentiful or scarce. A policy rate cannot lower input costs such as raw materials, labor, or electricity.
The Philippines is suffering from cost-push inflation. Mr. Remolona has said the pressure is mainly domestic supply shocks. October prices were pushed up by transport, electricity, housing and rice, in a country that imports almost all of its oil, and Nomura expects headline inflation to stay above seven percent through December. Gross domestic product grew 2.1 percent in the third quarter, the fifth consecutive quarter of slowing, and an economy that weak has no excess demand to drain. The hike drains what strength the economy still has.
Credit is the blood of commerce, and businesses use it for far more than expansion. The importer of raw materials depends on letters of credit, priced off bank funding cost. The manufacturer lives on trade credit, the 30 or 60 days a supplier allows before payment comes due. Business-to-business buy now, pay later terms run on borrowing. Raise the cost of money and every link in that chain pays more or gets cut off. The company then has two options. It raises prices to cover the financing, which adds fresh cost-push to the inflation the hike was meant to kill. Or it cuts output and jobs. Either way the remedy lands on the cost side of the problem it claims to relieve.
The patient was already short of blood. Public construction has contracted for six consecutive quarters as flood control investigations froze infrastructure spending, and gross capital formation fell 0.2 percent in the third quarter. Chinabank warns that private construction may decline as higher rates bite. The state has pulled back its construction spending, and the central bank is now pulling back private financing.
The BSP has a case. Hikes can support a weak currency, and core inflation has been rising, which the central bank reads as price pressures broadening into second-round effects. With the policy rate more than two percentage points below headline inflation, real borrowing costs are negative, and a central bank that tolerates that risks losing the expectations it spent years securing.
Those points are serious, and the peso touched P64 to the dollar on October 27, five days after the jumbo hike, a record low, so the hike did not hold the currency. Second-round effects are cost-push feeding on itself, and a hike reaches them only by cooling demand that has already cooled. Credibility comes from naming the problem correctly and a central bank that prescribes a demand-pull cure for a cost-push illness teaches the market that it will bleed the patient whenever prices rise.
The remedies for cost-push sit with the government: energy supply, transport, rice imports and the release of stalled public projects. Releasing those projects adds to supply and to growth, and it does not charge any interest.
Washington’s doctors had sharp lancets and sound intentions. They had the wrong diagnosis. How many more interest rate hikes can the economy survive?
E-mail me at mangun@gmail.com. Follow me on Twitter @mangunonmarkets. PSE stock-market information and technical analysis provided by AAA Southeast Equities Inc.